0000911916-17-000074.txt : 20170301
0000911916-17-000074.hdr.sgml : 20170301
20170301121630
ACCESSION NUMBER: 0000911916-17-000074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170301
FILED AS OF DATE: 20170301
DATE AS OF CHANGE: 20170301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CoLucid Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348649
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203419541
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 781-365-2596
MAIL ADDRESS:
STREET 1: 222 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Colucid Pharmaceuticals Inc
DATE OF NAME CHANGE: 20060104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lawton Alison Frances
CENTRAL INDEX KEY: 0001542650
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37358
FILM NUMBER: 17652635
MAIL ADDRESS:
STREET 1: 39 ROBINSON ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02420
FORMER NAME:
FORMER CONFORMED NAME: LAWTON ALISON FRANCIS
DATE OF NAME CHANGE: 20120216
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2017-03-01
1
0001348649
CoLucid Pharmaceuticals, Inc.
CLCD
0001542650
Lawton Alison Frances
C/O COLUCID PHARMACEUTICALS, INC.
222 THIRD STREET
CAMBRIDGE
MA
02142
1
0
0
0
Stock Option (Right to Buy)
6.54
2017-03-01
4
D
0
1420
39.96
D
2026-03-11
Common Stock
1420
0
D
Stock Option (Right to Buy)
6.24
2017-03-01
4
D
0
8897
40.26
D
2026-05-10
Common Stock
8897
0
D
Stock Option (Right to Buy)
36.20
2017-03-01
4
D
0
658
10.30
D
2027-01-03
Common Stock
658
0
D
Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
/s/ Christine G. Long, Attorney-in-Fact for Alison Lawton (power of attorney previously filed)
2017-03-01